EUVIMEDEUVIMED entdecken
Multizentrische Studie

A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

Luis Buzón-Martín iD, Maria Luisa Montes, Roberto Pedrero, María José Galindo, Mireia Santacreu-Guerrero, María Remedios Alemán, Miguel Torralba iD, Alberto Díaz de Santiago iD, Fran Fanjul, Adrián Rodríguez, Alfonso Cabello iD, María José Crusells und 47 weitere

Journal of Antimicrobial Chemotherapy · 02.12.2025 · 80 (12) · 3438-3451

DOI: 10.1093/jac/dkaf389 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 23.10.2025. Verfasst von Luis Buzón-Martín und 58 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Enfemedades Infecciosas, Hospital Universitario de Burgos, Burgos, Spain. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Pyridones, Anti-HIV Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Daily oral antiretroviral therapy (ART) has transformed HIV into a chronic, manageable condition, but it still poses psychological, logistical, and biological challenges. Long-acting injectable (LAI) cabotegravir plus rilpivirine provides an alternative for virologically suppressed individuals, reducing treatment fatigue, stigma, and daily dosing. While clinical trials have demonstrated efficacy and safety, real-world data remain limited. We assessed the effectiveness and safety of LAI cabotegravir plus rilpivirine in Spain.

Methods

RELATIVITY is a 5-year, multicentre, ambispective, non-controlled cohort study. The primary endpoint was treatment effectiveness, defined as the proportion of patients discontinuing LAI therapy for any reason, including loss of virological suppression (HIV-RNA >50 copies/mL) during follow-up, regardless of formal failure criteria.

Results

This interim analysis (cut-off: March 1, 2025) included 3203 patients from 58 Spanish hospitals; 57 were excluded due to detectable viral load at switch, leaving 3146 participants. Most were men (84.6%), with a median age of 45 years. Median time on ART before switching was 9.0 (5.0–15.0) years, and duration of viral suppression was 84.0 (36.0–132.0) months. Prior integrase inhibitor–based regimens were reported in 77.1%. Virological suppression was maintained in ≥96% through 23 months of follow-up. Overall, 6.4% (n = 199) discontinued, most frequently for injection-site reactions (n = 45), systemic adverse events (n = 29), or virological failure (n = 20).

Conclusions

Interim results from the RELATIVITY cohort confirm high effectiveness and safety of LAI cabotegravir plus rilpivirine in Spanish clinical practice, consistent with randomized trial outcomes and real-world data. An extended follow-up will provide further insights.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsPyridonesAnti-HIV AgentsHumansMaleSpainFemaleAdultMiddle AgedProspective StudiesViral LoadTreatment OutcomeDelayed-Action PreparationsDrug Therapy, CombinationHIV-1Diketopiperazines

Substanzen

RilpivirinecabotegravirPyridonesAnti-HIV AgentsDelayed-Action PreparationsDiketopiperazines

Autor:innen und Institutionen

  • Unidad de Enfemedades Infecciosas, Hospital Universitario de Burgos, Burgos, Spain.
  • Unidad de Enfermedades Infecciosas, Hospital Universitario La Paz, Madrid, Spain.
  • CIBERINFEC, Carlos III Health Institute, Madrid, Spain.
  • Fundación para la Investigación e Innovación Biomédica (FIIB) de los hospitales universitarios Infanta Leonor (Vallecas) y Sureste, Arganda del Rey, Madrid, Spain.
  • Unidad de Enfermedades Infecciosas, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Unidad de VIH, Hospital Universitario 12 de Octubre, Madrid, Spain.

ORCID-Profile: Luis Buzón-Martín, Miguel Torralba, Alberto Díaz de Santiago, Alfonso Cabello, Carmen Hidalgo-Tenorio, David Vinuesa, Juan Tiraboschi, Jara Llenas-García, Juan Emilio Losa, Mar Masiá, Juan José Corte, Jesús Troya

Zitieren

APA

Buzón-Martín, L., Montes, M. L., Pedrero, R., Galindo, M. J., Santacreu-Guerrero, M., Alemán, M. R., Torralba, M., Díaz de Santiago, A., Fanjul, F., Rodríguez, A., Cabello, A., Crusells, M. J., Navarro, M. D. C., Aguilera, M., Hidalgo-Tenorio, C., Morano-Amado, L. E., Vinuesa, D., De Andres, C., Bernal-Morell, E., …, & Troya, J. (2025). A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study). Journal of Antimicrobial Chemotherapy, 80(12), 3438-3451. https://doi.org/10.1093/jac/dkaf389

Vancouver

Buzón-Martín L, Montes ML, Pedrero R, Galindo MJ, Santacreu-Guerrero M, Alemán MR, et al. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study). Journal of Antimicrobial Chemotherapy. 2025;80(12):3438-3451. doi:10.1093/jac/dkaf389

BibTeX
@article{BuznMartn2025,
  author = {Buzón-Martín, Luis and Montes, Maria Luisa and Pedrero, Roberto and Galindo, María José and Santacreu-Guerrero, Mireia and Alemán, María Remedios and Torralba, Miguel and Díaz de Santiago, Alberto and Fanjul, Fran and Rodríguez, Adrián and Cabello, Alfonso and Crusells, María José and Navarro, María Del Carmen and Aguilera, María and Hidalgo-Tenorio, Carmen and Morano-Amado, Luis Emilio and Vinuesa, David and De Andres, Carlos and Bernal-Morell, Enrique and Martínez-Álvarez, Rosa María and Cabello-Clotet, Noemí and Tiraboschi, Juan and Montero, María Del Carmen and Vivancos-Gallego, María Jesús and Díez, Cristina and Calderón, Ruth and De Zárraga, Miguel Alberto and Gisbert, Laura and Romero-Palacios, Alberto and Cabo, Rebeca and Soler, Josefa Francisca and Sepúlveda, María Antonia and Sánchez-Guirao, Antonio Jesús and Escrich, Cristina and Arnaiz De Las Revillas, Francisco and Ferreira, Eva and Valentín, Beatriz and Lérida, Ana and Llenas-García, Jara and Gómez, Albert and Losa, Juan Emilio and Alonso, Bárbara and Sanz, José and Masiá, Mar and Pernas, Hadrian and Corte, Juan José and Garcinuño, María Ángeles and Gainzarain, Juan Carlos and Estébanez, Miriam and García-Navarro, María Del Mar and Barragán, Patricia and Ramos, Noemí and Clavero, Marta and Millán, Marta and Del Álamo, Míkel and Egido, Miguel and De La Calle, Beatriz and Ferrero, Oscar Luis and Troya, Jesús},
  title = {A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {12},
  pages = {3438--3451},
  doi = {10.1093/jac/dkaf389}
}
Kostenlos starten →